Rajesh Shrestha1, Smith Giri1, Ranjan Pathak1, Vijaya Raj Bhatt1. 1. Rajesh Shrestha, Division of Hospital Medicine, Department of Medicine, Rhode Island Hospital, Brown University, Rhode Island, RI 02903, United States.
Abstract
AIM: To determine the risk of second primary malignancy (SPM) and survival of patients with essential thrombocythemia (ET). METHODS: We identified all patients with ET diagnosed during 2001 to 2011 from the Surveillance, Epidemiology and End Results (SEER) 18 database. Actuarial and relative survival methods were used to calculate the survival statistics. We utilized the SEER 13 database to calculate SPM. We used multiple primary standardized incidence ratio (SIR) session of the SEER*Stat software (version 8.1.5) to calculate SIR and excess risk of SPM for ET patients. RESULTS: Age standardized five-year cause-specific survival was greater for patients < 50 years vs those ≥ 50 years (99.4% vs 93.5%, P < 0.01). Five-year cause-specific survival was lower for men vs women (70.2% vs 79.7%). A total of 201 patients (2.46%) developed SPM at a median age of 75 years. SPMs occurred at an observed/expected (O/E) ratio of 1.26 (95%CI: 1.09-1.45, P = 0.002) with an absolute excess risk (AER) of 37.44 per 10000 population. A significantly higher risk was noted for leukemia (O/E 3.78; 95%CI: 2.20-6.05, P < 0.001; AER 11.28/10000). CONCLUSION: ET patients have an excellent cause-specific five-year survival but are at an increased risk of SPM, particularly leukemia, which may contribute to excess deaths.
AIM: To determine the risk of second primary malignancy (SPM) and survival of patients with essential thrombocythemia (ET). METHODS: We identified all patients with ET diagnosed during 2001 to 2011 from the Surveillance, Epidemiology and End Results (SEER) 18 database. Actuarial and relative survival methods were used to calculate the survival statistics. We utilized the SEER 13 database to calculate SPM. We used multiple primary standardized incidence ratio (SIR) session of the SEER*Stat software (version 8.1.5) to calculate SIR and excess risk of SPM for ET patients. RESULTS: Age standardized five-year cause-specific survival was greater for patients < 50 years vs those ≥ 50 years (99.4% vs 93.5%, P < 0.01). Five-year cause-specific survival was lower for men vs women (70.2% vs 79.7%). A total of 201 patients (2.46%) developed SPM at a median age of 75 years. SPMs occurred at an observed/expected (O/E) ratio of 1.26 (95%CI: 1.09-1.45, P = 0.002) with an absolute excess risk (AER) of 37.44 per 10000 population. A significantly higher risk was noted for leukemia (O/E 3.78; 95%CI: 2.20-6.05, P < 0.001; AER 11.28/10000). CONCLUSION: ET patients have an excellent cause-specific five-year survival but are at an increased risk of SPM, particularly leukemia, which may contribute to excess deaths.
Entities:
Keywords:
Essential thrombocythemia; Second primary malignancy; Survival
Authors: F Passamonti; E Brusamolino; M Lazzarino; C Baraté; C Klersy; E Orlandi; A Canevari; G Castelli; S Merante; C Bernasconi Journal: Haematologica Date: 2000-10 Impact factor: 9.941
Authors: A Tefferi; E A Wassie; T L Lasho; C Finke; A A Belachew; R P Ketterling; C A Hanson; A Pardanani; N Gangat; A P Wolanskyj Journal: Leukemia Date: 2014-05-05 Impact factor: 11.528
Authors: Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda Journal: Blood Date: 2014-01-29 Impact factor: 22.113
Authors: Alexandra P Wolanskyj; Susan M Schwager; Rebecca F McClure; Dirk R Larson; Ayalew Tefferi Journal: Mayo Clin Proc Date: 2006-02 Impact factor: 7.616
Authors: Johanne M Holst; Trine L Plesner; Martin B Pedersen; Henrik Frederiksen; Michael B Møller; Michael R Clausen; Marcus C Hansen; Stephen Jacques Hamilton-Dutoit; Peter Nørgaard; Preben Johansen; Tobias Ramm Eberlein; Bo K Mortensen; Gustav Mathiasen; Andreas Øvlisen; Rui Wang; Chao Wang; Weiwei Zhang; Hans Beier Ommen; Jesper Stentoft; Maja Ludvigsen; Wayne Tam; Wing C Chan; Giorgio Inghirami; Francesco d'Amore Journal: Haematologica Date: 2019-11-28 Impact factor: 9.941